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MPTP: An Industrial Chemical and
Contaminant of Illicit Narcotics Stimulates a
New Era in Research on Parkinson's
Disease
by 1. J. Kopin*
MPTP (1-methyl4-phenyl-1,2,3,6-tetrahydropyridine) causes selective destruction ofdopaminergic neu-
rons of the nigrostriatal pathway in humans and other primates. It is less specific and much less potent
in mice and has only slight effects in rats. Differences in rates and sites of metabolism of MPTP to its
active, toxic, highly polar metabolite, MPP+ (1-methyl-4-phenylpyridine), appear to influence species
specificity. In rats, type B monoamine oxidase (MAO-B), which mediates the conversion of MPTP to
MPP+, may act as an enzymatic barrier at brain microvessels, whereas in primates the enzyme, present
mainly in astrocytes, appears important for bioactivation ofMPTP into the toxic metabolite. MPP+ is a
substrate for catecholamine uptake sites and is concentrated in these neurons. The molecular mechanism
of MPP+ toxicity has not been established definitively, but conversion to a free radical or uptake by
mitochondria and inhibition of mitochondrial respiratory enzymes, leading to calcium release and cell
death have been suggested. The discovery of toxin which causes an animal model of Parkinson's disease
has stimulated new research on environmental factors that might contribute to this progressive degen-
erative disorder and provides a means for assessing new approaches to therapy.
Introduction
It was recently discovered that drug abusers who
accidentally self-administered 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) developed, over a
period of a few days, a severe motor disorder which
closely resembles an advanced stage ofParkinson's dis-
ease (,2). MPTP is formed (Fig. 1) by the dehydration
of an intermediate compound required for the synthesis
of an active narcotic compound, 1-methyl-4-propionox-
ypyridine (MPPP), an analogue ofmeperidine. The tox-
icity of MPTP was not recognized until the occurrence
of the parkinsonian syndrome among these drug abu-
sers, but it is nowrecognized that several chemists who
had synthesized large quantities of MPTP as an indus-
trial intermediate developed parkinsonism as a conse-
quence of exposure to this toxin (3,4). Studies in pri-
mates have shown that the brain lesions, biochemical
alterations, and motor abnormalities found after MPTP
administration resemble closely those found in sponta-
neous Parkinson's disease (5-7). Duvoisin (8) has sum-
marized the epidemiological evidence that Parkinson's
disease is not likely to be a heritable disorder. This
evidence that environmental factors are important and
the discovery that exposure to a chemical substance can
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produce neurological deficits almost identical to those
of Parkinson's disease has excited new efforts at un-
derstanding the actions of MPTP and identifying en-
vironmental factors that might prevent or alleviate the
progression ofthe disease.
Mechanisms Influencing MPTP
Toxicity
A number of different, sometimes competing, pro-
cesses influence the ability of a toxin to attack and de-
stroy specific cells. Metabolism of the administered
agent may be responsible for bioactivation and/or de-
toxification of the compound or its metabolite; the rel-
ative rates of activation and detoxification may deter-
mine vulnerability. Diffusion or active transport ofthe
compound or its metabolite may limit or enhance tox-
icity by determining at which sites the toxin can reach
sufficiently high concentrations to interfere with vital
cellular processes. Cellular constituents may provide
defenses against the toxic effects or may facilitate the
actions of the toxin and thereby influence cellular vul-
nerability. The capacity of the cell to repair or replace
damaged organelles or enzymes can also be critical in
determining cell survival after a toxic insult. Many of
these factors appear to influence significantly MPTP
toxicity and may account for differences in species vul-I. J. KOPIN
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FIGURE 1. Chemical synthesis ofthe meperidine analogue, MPPP,
and the side reaction product, MPTP.
nerability as well as tissue specificity ofthe toxin. Low
doses of MPTP cause relatively specific damage to the
dopaminergic neurons in the nigrostriatal pathway of
primates and also are effective in dogs; larger doses are
required to affect mice, but specificity is lost in many
dopaminergic systems and even the noradrenergic neu-
rons are affected. Other rodents (rats, guinea pigs) ap-
pear almost invulnerable to the systemically adminis-
tered toxin.
Metabolism of MPTP to MPP+
MPTP is afat-soluble compound that is absorbed rap-
idly and freely penetrates membranes, including the
blood-brain barrier of mice and monkeys (9). Shortly
after administration of MPTP to monkeys, however, it
is almost completely converted to its quarternary de-
rivative, 1-methyl-4-phenyl-pyridine (MPP+), which is
formed in all tissues, including the brain (9,10). MPP+
persists inthebrain ofmonkeys for manydays (the half-
life has been estimated tobe about 10days), butrapidly
disappears from mouse brain (9). Enzymatic conversion
of MPTP to MPP+ was first demonstrated in rat (11)
and monkey (12) brain homogenates, but has subse-
quently been found to occur in homogenates or slices of
many tissues. Since formation ofMPP+ is mediated by
mitochondrial enzymes and is inhibited by drugs that
block type B monoamine oxidase (MAO-B) but not by
those that block only type A MAO (MAO-A), it is likely
that MAO-B is responsible for the oxidation of MPTP
(11). The oxidation appears to occur in two steps, with
1-methyl-4-phenyl-3,4,-dihydropyridine (MPDP+) as an
intermediate (Fig. 2). Conversion ofMPDP+ to MPP+
may proceed by spontaneous auto-oxidation or by the
action of MAO.
Formation of MPP+ is essential to MPTP toxicity
since inhibition of MAO-B, which blocks formation of
MPP+ and even elevates brain levels ofMPTP (9), pre-
vents the dopamine neuron-damaging effects (9,13,14).
The protective effect ofMAO-B inhibitors has been re-
peatedly demonstrated, in tissue cultures as well as in
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FIGURE 2. Metabolism of MPTP to MPP+.
vivo. The acute behavioral effects of MPTP, however,
do not appear to be the result of MPP+ formation be-
cause they are unaffected by pretreatment with MAO-
B inhibitors.
The localization of MAO-B may be an important de-
terminant of MPTP toxicity. MAO-B is not the major
form of MAO in dopaminergic neurons, but does pre-
dominate in astrocytes and serotonergic neurons (15) as
well as in blood vessel walls of some species. After IV
administration of 3H-MPTP, the distribution of radio-
activity in brain resembles that of3H-pargyline (16,17),
an irreversible MAO inhibitor. If MAO-B is present in
sufficientlyhighconcentrations incapillary orblood ves-
sel walls outside the blood-brain barrier, conversion of
MPTP to MPP+ at this site might limit entry of the
toxin into the brain, as MPP+ does not readily enter
brain. One dayafter3H-MPTP administration to a mon-
key, Markey et al. (9) found that arterial walls accu-
mulated the radiolabel as densely as did the locus coe-
ruleus, lateral parabrachial nucleus, and neostriatum.
In other species, vascular MAO-B may predominate.
Harik et al. (18) attribute the resistance ofrats to the
toxic effects of systemically administered MPTP to an
enzymatic barrier resulting from the high levels of
MAO-B inthe capillaries ofratbrain. Theyshowed that
3H-pargyline binding to rat brain microvessels was 10-
fold higher than binding to microvessels from human or
mouse brain and that most ofthe tritum was bound to
MAO-B. Furthermore, MPTP oxidation by rat cerebral
microvessels was 30-fold more rapid than by human
microvessels; mouse microvessels were intermediate in
MPTP-oxidizing capacity. The relative activities of
MAO-B in astrocytes or serotonergic neurons inside,
and capillary endothelium outside, of the blood-brain
barrier might regulate the toxicity of MPTP adminis-
tered directly into the brain, as well as by IVinjection.
Thus, while MPP+ administered into the neostriatum
of rats is toxic, MPTP injected in the same dose is not
(19). Although MPTP is toxic to dopaminergic neurons
in explants ofrat embryo mesencephalon (20), it is not
toxic when infused directly into the substantia nigra
(21).
Selective Uptake of MPP+ by
Catecholaminergic Neurons
While MAO-B inastrocytes andserotonergic neurons
may be responsible for the conversion of MPTP to
CH3
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MPP+ in brain, this does not explain the specificity of
MPTPtoxicityfordopaminergic neurons. MPP+, which
is a quartenary amine, diffuses with difficulty across
lipid membranes, but studies with astrocytes in tissue
culture have suggested that this compound can escape
into the surrounding media. MPP+ is taken up by syn-
aptosomes prepared from rat striatum or cortex; inhi-
bition ofthis uptake by various drugs indicates that the
uptake process for dopamine in the striatal synapto-
somes and for norepinephrine in cortical synaptosomes
is responsible for MPP+ accumulation (22). Pharmacol-
ogical inhibition of dopamine uptake blocks the neuro-
toxic effects ofMPTP in mice (23-25). Blockade by do-
pamine uptake inhibition of the toxic effects of MPTP
in monkeys has also been demonstrated, but protection
required administration ofthe inhibitor for weeks after
MPTP (26).
Uptake of MPP+ by catecholaminergic neurons ade-
quately explains the selectivity of the toxic effects in
mice. In this species, noradrenergic as well as most
dopaminergic neurons are affected, but the amine de-
pletion is often transient and few cells appear to have
been killed. There are wide variations in the vulnera-
bility of catecholaminergic neurons in mouse brain to
MPTPtoxicity. Dopaminergic neurons in C57BL/6mice
were found to be more sensitive to MPTP than were
those of NMRI or CBA/Ca mice and those of Swiss-
Webster mice least sensitive (27), but in C57BL/6 mice,
norepinephrine in the frontal cortex was not signifi-
cantly altered, whereas in the other strains there were
50 to 89% decreases in cortical norepinephrine. In an-
otherstudy, white BKWmicewereassensitive asblack
C57BL/6 mice to MPTP depletion of dopamine (28),
whereas noradrenergic neurons appeared least vulner-
able. Differences invulnerability amongSwiss-Webster
mice obtained from different supplies has also been
noted (29). Age, route ofMPTP administration, and sex
have also been cited as variables indeterminingtoxicity
ofMPTPinmonkeys aswellasmice. Thus, whileuptake
ofMPP+ into dopaminergic neurons appears to be nec-
essary for MPTP toxicity, this does not explain com-
pletely the neuronal specificity.
Binding of MPP+ to Neuromelanin
Neuromelanin is the pigmented substance that is re-
sponsible for the dark color of the substantia nigra in
primates and several other species. It is formed from
oxidation of dopamine (or other catechols) to quinones
which polymerize and are deposited on lipofuscin. Neu-
romelanin accumulates with age and is generally re-
garded as a waste product. The association between
neuromelanin content in primates and dogs and the rel-
ative vulnerability ofnigrostriatal neurons to MPTP in
these species contrasted with the almost complete ab-
sence ofneuromelanin in rodents, which are much less
vulnerable to the toxin. The parallel increase of neu-
romelanin and vulnerability to MPTP with age in pri-
mates suggested that neuromelanin might participate
in the toxic mechanism or its presence was indicative
of a lack of cellular defense mechanisms to protect
against damage. Vulnerability to MPTP, however, also
increases with age in mice (30) that lack brain neuro-
melanin. Neuromelanin binds MPP+ with relatively
high affinity (31), and it has been suggested that these
granules may store the MPP+. Slow release of MPP+
into the cytoplasmfromthis depot might maintain toxic
levels in the cytoplasm sufficiently long to cause irre-
versible cell damage and death. Chloroquin, which
blocks binding of MPTP to neuromelanin, appears to
decrease MPTP toxicity (32). Studies with radiolabeled
MPTP, however, show that the toxin accumulates only
in the cell terminals, not in the cell bodies where neu-
romelanin is located.
Mechanisms of Cellular Toxicity of MPP+
The accumulation and persistence ofMPP+ at nerve
terminals appearstoresult indamagetotheneuron and
may, in vulnerable cells, cause neuronal death. Several
hypotheseshavebeenproposedtoexplainthemolecular
mechanisms responsible for MPP+ toxicity. One group
of hypotheses suggests that free radical formation,
which canresultinproductionofsuperoxides, hydrogen
peroxide, hydroxyl free radicals, and a limited capacity
to protect against oxidative stress, is involved in MPP+
toxicity. Normally superoxide is converted to hydrogen
peroxide by superoxide dismutase and the hydrogen
peroxide is converted to water and oxygen by catalase.
Ifthese reactions do not proceed sufficiently rapidly to
remove superoxideorhydrogenperoxide, hydroxylfree
radicals can form. These free radicals can attack mem-
branes, organelles, DNA or RNA, carbohydrates, or
proteins, resulting in inactivation ofvital enzymes. Su-
peroxide dismutase, catalase, glutathione peroxidase,
and other soluble reducing substances protect the cell
fromaccumulation ofexcessfreeradicals, butwhenfree
radical formation is rapid and reductive agents are de-
pleted, these protective mechanisms may be inade-
quate.
The evidence for a role ofredox cycling and free rad-
ical involvement in MPP+ toxicity has been largely in-
direct. Although Sinhaet al. (33) could not demonstrate
by electron spin resonance free radical formation from
MPP+ under conditions in which paraquat free radicals
wereapparent, byusingaspin-trappingtechnique, they
did find significant stimulation by MPP+ of superoxide
and hydroxylradicalformation. Formation ofthese free
radicals occurred during incubation of NADPH cyto-
chrome P-450 reductase with NADPH in the presence
ofoxygen, but was less rapid than when paraquat was
used.
Diethyl dithiocarbamate (DCC), which chelates cop-
per and inhibits superoxide dismutase, potentiates the
toxicity of both paraquat (34) and MPTP (35) adminis-
tered to mice. DCC, however, also inhibits other cop-
per-dependent enzymes, including aldehyde dehydro-
genase. Ethanol, which is a good hydroxyl radical
scavenger, inhibits MPP+ potentiation of free radical
formation in vitro (33), but ethanol and its metabolite,
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acetaldehyde, potentiate the toxicity of MPTP in mice
(36), possibly by inhibiting superoxide dismutase.
Like paraquat, when administered systematically,
MPP+ causes severe toxic damage in the lungs and in-
creases plasma levels of glutathione disulfide, an indi-
cation ofoxidative stress (37). In isolated hepatocytes,
both MPP+ and paraquat rapidly deplete ATP and in
the presence of BCNU, an inhibitor of glutathione re-
ductase, decrease glutathione levels (38). Glutathione
depletionbyMPTP(39,40)doesnotappeartobeamajor
factor in its toxicity since agents that elevate glutathi-
one tissue levels fail to diminish MPP+ toxicity (41).
AttemptstopreventordiminishthetoxicityofMPTP
by treatment with one or more ofseveral antioxidants
administered tomicebefore, during, and afterthetoxin
have not been consistently successful. By treatment
with a-tocopherol (2.5 g/kg), p-carotene (100 mg/kg), 1-
ascorbic acid (100 mg/kg), or N-acetylcysteine (50 mg/
kg) daily for 5 days beginnring 2 days before adminis-
trationofthetoxin, Perry etal. (42)partiallyprevented
the depletion of striatal dopamine 1 month after the
administration of a single dose of MPTP (40 mg/kg).
Using similar methods, however, neither Baldessarini
et al. (43) nor Martinovits et al. (44) could demonstrate
any protection from the toxicity at 7 or 30 days.
Inhibition by MPP+ of Mitochondrial
Enzymes
Since interference with essential mitochondrial func-
tions could lead to cell death, effects of MPTP and its
metabolites on mitochondrial function became ofinter-
est.
In mitochondria isolated from rat or mouse brain,
MPP+ interferes with NADH-linked oxidation of py-
ruvate or glutamate without affecting the oxidation of
succinate. This suggests thatthe site ofinteractionwith
the respiratory process is at complex I (45). In slices of
mouse neostriatum, MPP+ or MPTP increase lactate
formation and enhance accumulation of glutamate and
aspartate, consistent with inhibition of mitochondrial
oxidation. These effects ofMPTP arepreventedbypre-
treatment with pargyline, indicating that the toxic ef-
fects are dependent on formation of MPP+ (46). This
suggests reversible inhibition by MPP+, but not by
MPTP, of NADH dehydrogenase cytochrome c reduc-
tase (47).
Ramsay et al. (48-50) and Frei and Richter (51)
showed that MPP+ is accumulated by an energy-de-
pendent uptake process into intact mitochondria. The
uptake process appears to be dependent on the electro-
chemical gradient of the mitochondrial membrane, as
valinomycin and K+, which collapse the gradient, abol-
ish MPP+ uptake. Mitochondrial uptake ofMPP+ is not
inhibited by dopamine uptake inhibitors (e.g., mazin-
dole), but is blocked by respiratory enzyme inhibitors
and uncouplers. MPP+ blockade of mitochondrial res-
piration is far less efficient in inverted mitochondria or
inisolatedmitochondrialinnermembranesthaninintact
mitochondria (50). This is consistent with the view that
high concentrations ofMPP+ are attained in intact mi-
tochondria as a result of its energy-dependent uptake
byintact mitochondria (49). Since calciumions interfere
with the uptake of MPP+ by isolated rat mitochondria
(51), it was thoughtthatthe ions might compete forthe
same electrochemicalgradient. Although neither6-OH-
DA nor MPP+ separately have much effect on the rate
of release of calcium sequestered in mitochondria, to-
gether they greatly increase the rate ofcalcium efflux.
MPTPinhibitscalciumeffluxandalmostcompletelypre-
vents the enhanced calciumrelease attendingcombined
MPP+-6-OH-DA treatment. Since excess calcium re-
lease has been implicated as acause ofcell death, itwas
suggested that the toxic effects ofMPTP might be me-
diated through release ofcalcium from mitochondria.
With glutamate or malate as substrates, the respi-
ratoryrate ofmitochondria frombrains of24-month-old
rats was lower than that of mitochondria from brains
of 2-month-old animals, and glutamate uptake was
markedly lower (52,53). There was no difference, how-
ever, when succinate was used as substrate. The rate
ofcalcium entry in mitochondria from aged rats is also
lower than the rate in mitochondria from young rats.
Itisperhapsnotfortuitousthatagingproduceschanges
in mitochondrial respiration and calcium distribution
similar to the effects ofMPP+ and that MPTP toxicity
increases with age.
Summary of Mechanisms Involved in
MPTP Toxicity
A schematic representation ofthe processes involved
in MPTP toxicity is shown in Figure 3. It is clear that
MPTP itself is not toxic and must be bioactivated by
conversion to MPP+. This is mediated by MAO-B.
MPP+, however, is averypolarcompound and doesnot
penetrate into the brain, but MPTP can easily diffuse
across the blood-brain barrier to reach astrocytes (or
other cells) that contain MAO-B. Ifformation ofMPP+
from MPTP in the endothelial cells is rapid, these cells
can act as an enzymatic barrier to entry ofMPTP into
the brain tissue. Measurements of total brain MPP+
would include the MPP+ in the endothelial cells, but it
might be expected that the MPP+ in these cells would
be lost rapidly. It has been proposed that high levels of
endothelial MAO-B protect rats from MPTP toxicity.
Once in the brain, MPTP is converted to MPP+ in as-
trocytes and the quarternary amine taken up into cat-
echolaminergic neurons. The molecular mechanisms re-
sponsible for MPP+ toxicity have not been definitively
established, but interactions with neuromelanin, pos-
sible free-radical formation, or concentration in mito-
chondria with consequent blockade of oxidative en-
zymes have been suggested. The wide variability of
regional vulnerability in monkey species, mice strains,
and even among humans exposed to MPTP, in addition
to differences in the neurons themselves, suggests that
several ofthese processes may act in concert to deter-
minethe levels ofMPP+ to which neurons are exposed.MPTP NEUROTOXICITY AND PARKINSON'S DISEASE
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FIGURE 3. Schematic representation of the processes involved in MPTP toxicity. MAO-B in the capillary endothelium may serve as an
enzymatic barrier to entry of MPTP by converting it to MPP+, which cannot penetrate the blood-brain barrier. If MPTP diffuses into the
brain, it can be metabolized by astrocyte (or serotoninergic neuronal) MAO-B to MPP+. When MPTP leaves the astrocyte, the specific
dopamine uptake mechanism can concentrate the toxin in the cytoplasm. The mechanisms of toxicity may involve neuromelanin storage
and release of MPP+, free radical formation, or direct attack on mitochondrial oxidative enzymes (see text).
Impact of the Discovery of MPTP
Toxicity on Parkinson's Disease
Research
The realization that nigrostriatal dopaminergic neu-
rons are particularly vulnerable to a toxin and that the
relative specific damage to this system can produce all
the cardinal signs and symptoms ofParkinson's disease
has stimulated new hypotheses regarding the patho-
genesis ofthis disorder. Asindicatedabove, Parkinson's
disease is normally not a heritable disorder. Stimulated
by the hypothesis that an environmental toxin may be
responsible for the development ofParkinson's disease,
a number ofinvestigators have sought to identify other
compounds that mayproduce similartoxic changes. The
vulnerability of mice to MPTP toxicity has provided a
useful means of screening such compounds (54). It is
evident, however, that in order for these analogues to
be active, they must be able to penetrate into brain, be
converted to a toxic analogue ofMPP+ which is a sub-
strate forthedopamine uptake site and, afterentry into
the neuron, interfere with a vital process. Several such
analogues of MPTP have been found (e.g., 2'-methyl-
MPTP, 4'-fluoro-MPTP, 4'-amino-MPTP), but as might
be expected, there are species differences in vulnera-
bility to these toxins. It is clear, however, that the N-
methyl group, the unsaturated pyridine ring, and the
4-aromatic ring are necessary for the toxic effects. It
has been proposed that the enzymatic N-methylation
might bioactivate a molecule lacking this group (53),
expandingthepossiblenumberofsubstancesthatmight
be converted to a specific dopaminergic neuronal toxin.
The ability of inhibitors of MAO-B to block the tox-
icity of MPTP and the report by Birkmayer et al. (56)
that deprenyl, a specific MAO-B inhibitor, not only po-
tentiatesthetherapeuticefficacyofL-Dopabutprolongs
life expectancy of patients with Parkinson's disease,
stimulated further speculation on the role ofMAO-B in
bioactivation of an environmental agent to produce a
toxin that is responsible for the degenerative process
responsible for progression ofthe disease. Indeed, clin-
ical trials designed to examine the influence ofdeprenyl
in arresting or slowing the progression of Parkinson's
disease have been instituted.
The availability of ananimalmodelthatfaithfully em-
ulates the spontaneous human motor disorder provides
a useful test system with which to evaluate new ther-
apeutic agents. Byinfusing MPTP into acarotid artery,
monkeys have been made hemiparkinsonian (57). These
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animals are able to feed themselves and survive well
without treatment with L-dopa or dopamine agonists.
Spontaneous motoractivity consistently results inturn-
ing toward the lesioned side, but when dopamine ago-
nists are administered, the direction of turning is re-
versed as a result of stimulation of supersensitive
receptors on the lesioned side. The rate and duration
ofthe reversed turning are dose dependent and provide
a means for quantification of drug efficacy.
Both hemiparkinsonism and fully parkinsonian ani-
mals have been subjected to tissue transplants using
adrenal medulla or fetal mesencephalon cells. These
transplants survive, produce dopamine, may stimulate
additional sprouting ofsurviving dopaminergic neurons
(e.g., from the ventral area), and result in functional
recovery. The improvement is transient with adrenal
medullary tissue, but fetal tissue transplants appear to
survive for at least half a year (58).
Thus, as the result of the tragic and dramatic acci-
dental discovery ofthe toxicity of MPTP, new studies
ofthe pathogenesis and treatments of Parkinson's dis-
ease have been stimulated and improve prospects for
preventing, arresting, or even reversing the progres-
sion ofthe degenerative processes responsible for neu-
ronal cell death.
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